Merck's Experimental Drug Shows Promise in Mid-Stage Study

Merck has announced that its experimental drug has met the primary goal of a mid-stage study in patients suffering from hidradenitis suppurativa, a chronic skin disease.

The condition causes painful lumps, abscesses, and scarring, and affects millions worldwide. Merck's drug was tested on patients with moderate-to-severe cases of the disease.

According to the study results, the experimental treatment showed improvement in reducing the number of inflammatory lesions, a key indicator for patients with hidradenitis suppurativa.